AF
NKTR icon

Allworth Financial’s Nektar Therapeutics NKTR Stock Holding History

Allworth Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49K Buy
681
+5
+0.7% +$285 ﹤0.01% 2343
2025
Q4 		$28.6K Hold
676
– – ﹤0.01% 2576
2025
Q3 		$38.5K Sell
676
-2,690
-80% -$89K ﹤0.01% 2287
2025
Q2 		$87K Buy
3,366
+2,690
+398% +$30.2K ﹤0.01% 1620
2025
Q1 		$7.49K Hold
676
– – ﹤0.01% 2560
2024
Q4 		$9.31K Hold
676
– – ﹤0.01% 2467
2024
Q3 		$13.2K Hold
676
– – ﹤0.01% 2137
2024
Q2 		$14.1K Buy
676
+16
+2% +$337 ﹤0.01% 2078
2024
Q1 		$9.25K Hold
660
– – ﹤0.01% 2146
2023
Q4 		$5.59K Buy
+660
New +$5K ﹤0.01% 2231
2022
Q4 		– Sell
-3
Closed – – 3135
2022
Q3 		$0 Buy
+3
New +$178 ﹤0.01% 2947
2022
Q2 		– Sell
-2
Closed – – 2654
2022
Q1 		$0 Sell
2
-18
-90% -$2.66K ﹤0.01% 2282
2021
Q4 		$4K Sell
20
-26
-57% -$5.64K ﹤0.01% 1606
2021
Q3 		$12K Buy
+46
New +$11.1K ﹤0.01% 1230
2019
Q1 		– Sell
-39
Closed -$19K – 1008
2018
Q4 		$19K Hold
39
– – ﹤0.01% 422
2018
Q3 		$36K Hold
39
– – ﹤0.01% 335
2018
Q2 		$28K Sell
39
-11
-22% -$12.7K ﹤0.01% 355
2018
Q1 		$80K Hold
50
– – 0.01% 198
2017
Q4 		$45K Hold
50
– – ﹤0.01% 261
2017
Q3 		$18K Buy
+50
New +$15.6K ﹤0.01% 381

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Allworth Financial's NKTR Position: Q1 2026 in Review

Allworth Financial increased its Nektar Therapeutics (NKTR) stake by 0.74% in Q1 2026, buying an estimated $285 and bringing the position to 681 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Allworth Financial first reported a position in NKTR in Q3 2017 and has held it in 20 quarters since. The position peaked at $87K in Q2 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Allworth Financial held 681 shares of Nektar Therapeutics worth $49K as of Q1 2026.
  • Allworth Financial bought 5 Nektar Therapeutics shares in Q1 2026, an estimated $285.
  • Nektar Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #2343 holding.
  • Allworth Financial first reported a position in Nektar Therapeutics in Q3 2017 and has held it in 20 quarters since.
  • Allworth Financial's Nektar Therapeutics position peaked at $87K in Q2 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.